Skip to main content
OpenTrials
Completed

NCT Number: NCT03685084

Investigation of AAI101 Safety, Tolerability & PK in Healthy Volunteers

* To assess the safety and tolerability of single and multiple ascending intravenous doses of AAI101 (SAD & MAD) in healthy male subjects. * To assess the safety and tolerability of single and multiple ascending intravenous doses of AAI101 in combination with fixed intravenous doses of piperacillin or cefepime in healthy male subjects

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Age range

18 year–45 year

Sex eligibility

Male

Study type

Interventional

Phase

Phase 1

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Male healthy volunteers aged between 18 and 45 years (inclusive) at screening.
  • Body mass index (BMI) of 18.0 to 30.0 Kg/m2 (inclusive) at screening.
  • Healthy as determined by the investigator on the basis of medical history, physical examination findings, clinical laboratory test results, vital sign measurements, and digital 12 lead ECG readings (all results were to be within normal range or considered non-clinically significant by the investigator).
  • Non-smoker or smoker of fewer than 10 cigarettes per day as determined by medical history. Had to be able to abstain from smoking during the inpatient stay.
  • Ability to communicate well with the investigator in the local language, and to understand and comply with the requirements of the study.

Main Exclusion Criteria:

  • Any significant cardiovascular (e.g., hypertension), hepatic, renal, respiratory (e.g., childhood asthma), gastrointestinal, endocrine (e.g., diabetes, dyslipidemia), immunologic, hematological, neurologic, or psychiatric disease.
  • Acute disease state (e.g., nausea, vomiting, fever, diarrhea) within 7 days before study Day 1.

Treatment and study plan

AAI101 i.v.

Drug

600 mg, 1 g, 2 g, 4 g, 1 g (every 6h), 2 g (every 6h)

Other names: AAI101

Saline 0.9% infusion

Drug

Vehicle infusion

Other names: Vehicle

Piperacillin i.v.

Drug

piperacillin 3 g i.v.

Other names: Beta-lactam antibiotic

Cefepime i.v.

Drug

cefepime 1 g i.v.

Other names: Beta-lactam antibiotic

Primary outcomes

  1. Safety Profile - Number of Subjects With at Least one Adverse Event

    Time frame: Throughout the period that subjects receive study drug up to 5 days following discontinuation of study treatment

    Safety will be evaluated from reported signs and symptoms and clinical laboratory tests

Secondary outcomes

  1. AAI101 maximum plasma concentration (Cmax)

    Time frame: Up to 24 hours post-dose

    Cmax will be compared before and after administration of AAI101 either alone or in the presence of cefepime or piperacillin

  2. AAI101 Clast

    Time frame: Up to 24 hours post-dose

    Clast will be compared before and after administration of AAI101 either alone or in the presence of cefepime or piperacillin

  3. AAI101 AUC(0-t) - AUC(0-8)

    Time frame: Up to 24 hours post-dose

    AAI101 Urea Under the Curve will be compared before and after administration of AAI101 either alone or in the presence of cefepime or piperacillin

  4. AAI101 half life (t1/2)

    Time frame: Up to 24 hours post-dose

    AAI101 t1/2 plasma pharmacokinetic parameter will be compared for AAI101 alone or in the presence of cefepime or piperacillin

Sponsors and collaborators

Lead sponsor

Allecra

Industry

Registry information

Official study title

Phase I, Single and Multiple Ascending Dose Study to Investigate the Safety, Tolerability and Pharmacokinetics of AAI101 Administered Intravenously Alone or in Combination With Piperacillin or Cefepime to Healthy Adult Subjects

Important dates

Study start
2013
Primary completion
2014
Study completion
2014
First posted
Sep 26, 2018
Registry last updated
Sep 26, 2018

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.